Press release
Synovial Sarcoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla
Synovial Sarcoma Clinical Trials
According to DelveInsight, the Synovial Sarcoma pipeline includes over 15 major companies actively developing more than 20 therapeutic candidates for the treatment of Synovial Sarcoma.
Synovial Sarcoma Overview:
Synovial sarcoma is a rare type of soft tissue cancer that usually develops near joints or tendons, most frequently in the arms and legs, though it can arise in other locations as well. Despite its name, it does not originate from synovial tissue; instead, it is linked to a specific genetic alteration-a translocation between chromosomes X and 18 (t(X;18))-that drives abnormal tumor growth.
This cancer primarily affects adolescents and young adults between the ages of 15 and 40, with a slightly higher incidence in males. Synovial sarcoma often grows slowly, which can make early diagnosis challenging. Common symptoms include swelling, a noticeable mass near a joint, pain, and tenderness. In more advanced cases, the tumor may involve nearby muscles, nerves, or bones, resulting in joint dysfunction and limited mobility.
Request for a detailed insights report on Synovial Sarcoma pipeline insights [https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Synovial Sarcoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Synovial Sarcoma Therapeutics Market.
Key Takeaways from the Synovial Sarcoma Pipeline Report
*
DelveInsight's Synovial Sarcoma pipeline report highlights a dynamic landscape, featuring over 15 active companies developing more than 20 therapeutic candidates for Synovial Sarcoma.
*
Leading companies in this space-including Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar, and others-are investigating novel therapies aimed at improving treatment outcomes for patients. Notable pipeline candidates in various stages of development include OTSA101, Tazemetostat, AL3818, among others.
*
Following the approval of Tecelra, Adaptimmune Therapeutics is exploring additional applications of its TCR technology. In February 2025, the FDA granted Breakthrough Therapy Designation to letetresgene autoleucel (lete-cel) for the treatment of myxoid/round cell liposarcoma (MRCLS), reflecting its potential to advance sarcoma therapies.
*
Earlier, on August 2, 2024, the FDA granted accelerated approval to Tecelra (afamitresgene autoleucel) for adults with unresectable or metastatic synovial sarcoma who had previously received chemotherapy. Tecelra is notable as the first gene therapy approved for this patient group and the first engineered T-cell receptor (TCR) therapy authorized for a solid tumor.
Synovial Sarcoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Synovial Sarcoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Synovial Sarcoma market.
Download our free sample page report on Synovial Sarcoma pipeline insights [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Synovial Sarcoma Emerging Drugs
*
AL3818: Advenchen Laboratories
*
Tazemetostat: Ipsen
*
OTSA101: OncoTherapy Science
Synovial Sarcoma Companies
More than 15 leading companies are actively working on therapies for Synovial Sarcoma, with Advenchen Laboratories having a drug candidate currently in the most advanced stage of development, Phase III.
DelveInsight's report covers around 20+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Synovial Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Synovial Sarcoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Synovial Sarcoma Therapies and Key Companies: Synovial Sarcoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Synovial Sarcoma Pipeline Therapeutic Assessment
- Synovial Sarcoma Assessment by Product Type
- Synovial Sarcoma By Stage
- Synovial Sarcoma Assessment by Route of Administration
- Synovial Sarcoma Assessment by Molecule Type
Download Synovial Sarcoma Sample report to know in detail about the Synovial Sarcoma treatment market @ Synovial Sarcoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Synovial Sarcoma Current Treatment Patterns
4. Synovial Sarcoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Synovial Sarcoma Late-Stage Products (Phase-III)
7. Synovial Sarcoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Synovial Sarcoma Discontinued Products
13. Synovial Sarcoma Product Profiles
14. Synovial Sarcoma Key Companies
15. Synovial Sarcoma Key Products
16. Dormant and Discontinued Products
17. Synovial Sarcoma Unmet Needs
18. Synovial Sarcoma Future Perspectives
19. Synovial Sarcoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Synovial Sarcoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/synovial-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=synovial-sarcoma-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-advenchen-laboratories-ipsen-oncotherapy-science-c4-therapeutics-takara-bio-bioatla]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Synovial Sarcoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla here
News-ID: 4161229 • Views: …
More Releases from ABNewswire
Xu Xu's Dumplings Food Truck Is Austin's Next Hit
It hasn't taken long for Xu Xu's Dumplings to become one of Austin's most talked-about new food trucks. Since its debut, locals have been raving about its delicate, flavorful dumplings - crafted daily by hand and served with a modern twist. Now, the team is gearing up for its official Grand Opening celebration on October 24, welcoming guests to its new home at 1234 East 6th Street, Austin, TX 78702.
A…
Trusted Roofing Contractors in Littleton, CO Ensuring Quality Roof Protection
Homeowners in Littleton, CO, have seen an increasing demand for dependable roofing contractors who understand the unique weather challenges of the region. From snow accumulation to hailstorms and UV exposure, Colorado roofs endure a wide range of conditions that require professional attention. Experienced roofing contractors bring technical skill, high-quality materials, and attention to detail to every project.
Homeowners in Littleton, CO, have seen an increasing demand for dependable roofing contractors who…
MovingExpert.org Launches as the Definitive Guide for Vetted Moving Companies in …
Minneapolis, MN - MovingExpert.org [https://movingexpert.org/], a new independent review platform, announced its official launch today. The site is dedicated to simplifying the difficult search for reliable moving companies, with an initial focus on key Midwest states. The platform provides unbiased, expert-driven rankings of the best movers in Minnesota, South Dakota, and Wisconsin.
Finding a trustworthy moving company is a major challenge for many families and individuals, often involving hours of research…
Top Dynamics Partners Emerges as a Leading Directory for Microsoft Dynamics 365 …
Fargo, ND - October 23, 2025 - Top Dynamics Partners establishes itself as a premier online directory for Microsoft Dynamics 365 implementation partners, connecting businesses with top Microsoft Dynamics partners worldwide. As a trusted resource in the Microsoft Dynamics 365 partners list, Top Dynamics Partners provides a platform to discover reliable Dynamics 365 partners, helping organisations find the right expertise for their enterprise resource planning (ERP) and customer relationship management…
More Releases for Synovial
Synovial Sarcoma Market Projected to Reach USD 420 Million by 2034
Synovial sarcoma (SS) is a rare and aggressive form of soft tissue sarcoma, most commonly affecting adolescents and young adults. Though it accounts for only 5-10% of all soft tissue sarcomas, its rarity and severity make it a significant focus of rare cancer research. The disease is characterized by its chromosomal translocation (t(X;18)) and its tendency to metastasize, primarily to the lungs, creating challenges in long-term patient survival.
Download Full PDF…
Synovial Sarcoma Market Clinical Advancements and Commercial Forecast
Synovial sarcoma is a rare, aggressive soft tissue cancer that typically arises near the joints of the arm or leg but can occur in other parts of the body. Although it accounts for less than 10% of all soft tissue sarcomas, synovial sarcoma often affects young adults and adolescents, making it a critical area of oncology research. Due to limited treatment options and poor survival outcomes, there has been an…
Synovial Sarcoma Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Synovial…
Synovial Sarcoma Market Size, Share, Report and Forecast 2024-2032
The synovial sarcoma market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by increasing research activities in targeted therapy development.
Synovial Sarcoma: Introduction
Synovial sarcoma is a rare and aggressive type of soft tissue cancer, primarily affecting young adults. It often arises near large joints, especially the knees, though it can occur anywhere in the body. Despite its name, it's not related to…
Synovial Sarcoma Market Analysis: Growth, Trends, and Key Players
The Synovial Sarcoma Market is set for substantial expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 4% during the forecast period spanning from 2024 to 2032. This growth can be attributed to various factors such as the increasing incidence of synovial sarcoma, advancements in medical technology, and the development of targeted therapies. In this comprehensive blog post, we will provide an in-depth overview of the Synovial Sarcoma Market,…
Synovial Sarcoma Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Synovial Sarcoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Synovial Sarcoma market size…
